For example, cyclic fatty acids (CFAs) can promote ferroptosis through ETC activation in sarcoma but may have antagonistic effects due to FXR activation in liver cancer, suggesting the need to establish precise intervention programs based on tumor metabolic heterogeneity [43,52]. The gene discussed is NR1H4; the disease is neoplasm.